Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Recruiting Not applicable

Augmentation of Partial Anterior Cruciate Ligament Tear: Early Results

NCT05391672 · tracked via the Priya Life Science Egypt tracker
Phase
Not applicable
Started
2022-06-09
Last updated
2025-12-22

Condition(s) studied

ACL InjuryACL Augmentation

Investigational drug(s) / intervention(s)

we will do ACL augmentation surgery to the patients who have partial ACL tear

we will do ACL augmentation surgery to the patients who have partial ACL tear: we will do ACL augmentation surgery to the patients who have ACL partial tear using hamstring graft and fixation of the graft to the femoral part by adjustable loop and tibial part with Bio or peak screws +\\- staples.

Study summary

Clinical evaluation for the patients with partial ACL tear who had ACL augmentation

Eligibility

Sex
ALL
Min age
15 Years
Max age
50 Years
Healthy volunteers
No
Inclusion Criteria: * age from 15 to 50 years old * Partial ACL tear without any other ligament injury * with and without meniscal tear * with and without knee deformity * recent and chronic injury Exclusion Criteria: * younger than 15 and older than 50 y * multiligament injury * complete ACL tear * failed ACL reconstruction or repair

Primary outcome measure(s)

  • The main outcome is difference in IKDC scores between the patients — Baseline
    we will evaluate the clinical outcome post operative mainly according to the difference in IKDC score between the patients

Trial sites (1)

FacilityCityRegionStatus
Assiyt University Asyut Egypt Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05391672 on ClinicalTrials.gov ↗ ← All trials in Egypt